Provided by Tiger Fintech (Singapore) Pte. Ltd.

FibroGen

10.77
-0.4100-3.67%
Volume:11.06K
Turnover:121.03K
Market Cap:43.55M
PE:-21.03
High:11.08
Open:10.97
Low:10.75
Close:11.18
52wk High:21.94
52wk Low:4.50
Shares:4.04M
Float Shares:3.62M
Volume Ratio:0.16
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5122
EPS(LYR):-11.8895
ROE:-1015.79%
ROA:-16.40%
PB:-0.20
PE(LYR):-0.91

Loading ...

FGEN Announces Share Buyback and Voting Rights Update

TIPRANKS
·
Aug 22

FibroGen Inc. Gains Approval from China for Sale of FibroGen China to AstraZeneca, Closing Expected in Q3 2025

Reuters
·
Aug 18

FibroGen Inc - Sale of FibroGen China on Track to Close in 3Q 2025

THOMSON REUTERS
·
Aug 18

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

THOMSON REUTERS
·
Aug 18

FibroGen Second Quarter 2025 Earnings: Misses Expectations

Simply Wall St.
·
Aug 14

FibroGen Amends Financing Agreement with Morgan Stanley

TIPRANKS
·
Aug 14

FibroGen Inc. Reduces Cash Balance Requirement with Fourth Amendment to Financing Agreement

Reuters
·
Aug 14

Foresight Environmental Infrastructure Limited Expands Treasury Shares

TIPRANKS
·
Aug 13

FibroGen Shares up 14.8% After Q2 Results, Cash Flow Update

THOMSON REUTERS
·
Aug 12

Top Premarket Gainers

MT Newswires Live
·
Aug 12

FibroGen Q2 EPS $(1.88) Beats $(2.25) Estimate, Sales $1.35M Miss $2.63M Estimate

Benzinga
·
Aug 12

FibroGen Inc. Reports Q2 2025 Financial Results; Sale of FibroGen China to Boost Cash Runway into 2028

Reuters
·
Aug 12

FibroGen Inc: Upon Close of Sale of FibroGen China, Cash Runway Extended Into 2028

THOMSON REUTERS
·
Aug 12

FibroGen Inc - Sale of FibroGen China to AstraZeneca Expected to Be for $210 Mln

THOMSON REUTERS
·
Aug 12

Analysts Are Bullish on These Healthcare Stocks: FibroGen (FGEN), Revolution Medicines (RVMD)

TIPRANKS
·
Aug 11

FibroGen Inc expected to post a loss of $2.31 a share - Earnings Preview

Reuters
·
Aug 09

FibroGen Inc : H.c. Wainwright Adjusts Target Price to $43 From $10 to Reflect 1-for-25 Reverse Stock Split

THOMSON REUTERS
·
Aug 07

FibroGen announces positive Type C meeting with FDA for roxadustat

TIPRANKS
·
Aug 07

FibroGen Inc. Receives Positive FDA Feedback for Advancing Roxadustat in Phase 3 Trial for Anemia in Lower-Risk Myelodysplastic Syndromes

Reuters
·
Aug 07

FibroGen Announces Positive Type C Meeting With the FDA for Roxadustat in Patients With Anemia Associated With Lower-Risk Myelodysplastic Syndromes

THOMSON REUTERS
·
Aug 07